Association between ADAM17 promoter polymorphisms and ischemic stroke in a Chinese population

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 8, 2014, Pages 878-893

  Li, You ^a   Cui, Li Li ^a   Li, Qian Qian ^a   Ma, Guo Da ^a   Cai, Yu Jie ^a   Chen, Yan Yan ^a   Gu, Xue Feng ^a   Zhao, Bin ^a   Li, Ke Shen ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

ADAM17; Ischemic stroke; Polymorphism

Indexed keywords

DISINTEGRIN; HIGH DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

AGED; ARTICLE; B SCAN; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; CHINA; COMPARATIVE STUDY; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE;

ADAM PROTEINS; AGED; BRAIN ISCHEMIA; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHINA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROKE;

EID: 84906805650     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.22400     Document Type: Article

References (39)

1. Lo AC, Guarino PD, Richards LG, Haselkorn JK, Wittenberg GF, Federman DG, Ringer RJ, Wagner TH, Krebs HI, Volpe BT: Robot-assisted therapy for long-term upper-limb impairment after stroke. N Engl J Med, 2010; 362: 1772-1783
2. Pelisek J, Eckstein H-H, Zernecke A: Pathophysiological mechanisms of carotid plaque vulnerability: impact on ischemic stroke. Arch Immunol Ther Exp (Warsz), 2012; 60: 431-442
3. Saftig P, Reiss K: The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic potential? Eur J Cell Biol, 2011; 90: 527-535
4. van der Vorst EP, Keijbeck AA, de Winther MP, Donners MM: A disintegrin and metalloproteases: molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis, 2012; 224: 302-308
5. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A: The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol, 2012; 91: 472-485
6. Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Jarvinen O, Salenius JP, Ozsait B, Komurcu-Bayrak E, Erginel-Unaltuna N, Huovila AP, Kytomaki L, Soini JT, Kahonen M, Karhunen PJ, Laaksonen R, Lehtimaki T: ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries--Tampere vascular study. Ann Med, 2009; 41: 279-290
7. Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y, Nakamura M: The expression of TNF-α converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest, 2008; 38: 97-105
8. Canault M, Leroyer AS, Peiretti F, Leseche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G: Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol, 2007; 171: 1713-1723
9. Holdt LM, Thiery J, Breslow JL, Teupser D: Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol, 2008; 28: 1097-1103
10. Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, Rupprecht HJ, Lackner K, Barbaux S, Poirier O, Peiretti F, Nalbone G, Juhan-Vague I, Blankenberg S, Tiret L: Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med (Berl), 2008; 86: 1153-1161
11. Junyent M, Parnell LD, Lai CQ, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M, An P, Smith CE, Lee YC, Borecki I, Ordovas JM: ADAM17_i33708A＞G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study. Nutr Metab Cardiovasc Dis, 2010; 20: 698-705
12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41
13. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet, 1991; 337: 1521-1526
14. Wang M, Li Y, Lu Y, Zuo X, Wang F, Zhang Z, Jia J: The relationship between ADAM17 promoter polymorphisms and sporadic Alzheimer’s disease in a Northern Chinese Han population. J Clin Neurosci, 2010; 17: 1276-1279
15. Pittock SJ, Meldrum D, Hardiman O, Thornton J, Brennan P, Moroney JT: The Oxfordshire Community Stroke Project classification: correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. J Stroke Cerebrovasc Dis, 2003; 12: 1-7
16. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A: The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol, 2012; 91: 472-485
17. Claesson-Welsh L: ADAM-mediated shedding, a new flavor in angiogenesis regulation. Arterioscler Thromb Vasc Biol, 2010; 30: 2087-2088
18. Edwards DR, Handsley MM, Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med, 2008; 29: 258-289
19. Pelisek J, Pongratz J, Deutsch L, Reeps C, Stadlbauer T, Eckstein HH: Expression and cellular localization of metalloproteases ADAMs in high graded carotid artery lesions. Scand J Clin Lab Invest, 2012; 72: 648-656
20. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, Taylor J, Burnett E, Gut I, Farrall M, Lathrop GM, Abecasis GR, Cookson WO: A genome-wide association study of global gene expression. Nat Genet, 2007; 39: 1202-1207
21. Luo Y, Wang Z, Li J, Xu Y: Serum CRP concentrations and severity of ischemic stroke subtypes. Can J Neurol Sci, 2012; 39: 69-73
22. Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S: Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke, 2007; 38: 2895-2899
23. Dollery CM, Libby P: Atherosclerosis and proteinase activation. Cardiovasc Res, 2006; 69: 625-635
24. Back M, Ketelhuth DF, Agewall S: Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis, 2010; 52: 410-428
25. Li Y, Liao F, Yin XJ, Cui LL, Ma GD, Nong XX, Zhou HH, Chen YF, Zhao B, Li KS: An Association Study on ADAM10 Promoter Polymorphisms and Atherosclerotic Cerebral Infarction in a Chinese Population. CNS Neurosci Ther, 2013;
26. Goswami B, Rajappa M, Singh B, Ray P, Kumar S, Mallika V: Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease. Cardiovasc J Afr, 2010; 21: 103-108
27. MM RA: [Tumor necrosis factor-α, insulin resistance, the lipoprotein metabolism and obesity in humans]. Nutricion hospitalaria: organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral, 2012; 27: 1751-1757
28. Lacerda L, Opie LH, Lecour S: Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes. Exp Diabetes Res, 2012; 2012: 502654
29. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS, Grinspoon SK: TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab, 2011; 96: E146-150
30. Rose-John S: ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res, 2013; 71: 19-22
31. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jen kinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokka R, Federici M, Tripathy D, DeFronzo RA, Folli F: Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia, 2009; 52: 2169-2181
32. Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M: The role of ADAM17 in metabolic inflammation. Atherosclerosis, 2013; 228: 12-17
33. Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M: TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes, 2012; 61: 454-462
34. Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schillaci O, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M: Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol, 2012; 32: 74-81
35. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, Lang KS, Haussinger D, Wakeham A, Itie-Youten A, Khokha R, Ohashi PS, Blobel CP, Mak TW:iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science, 2012; 335: 229-232
36. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M: Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science, 2012; 335: 225-228
37. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M: TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes, 2009; 58: 2396-2401
38. Szalad A, Katakowski M, Zheng X, Jiang F, Chopp M: Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J Exp Clin Cancer Res, 2009; 28: 129
39. Mizui Y, Yamazaki K, Sagane K, Tanaka I: cDNA cloning of mouse tumor necrosis factor-alpha converting enzyme (TACE) and partial analysis of its promoter. Gene, 1999; 233: 67-74